IgG is the most common type of antibody in your blood. It's part of your immune system, helping fight off infections. Think of it like a shield that protects you from germs.
Every report comes from a Lived member, sent anonymously.
No reports yet
Add what worked for you with the search bar below
Immunoglobulin G (IgG) is the most common type of antibody in the blood: the proteins the immune system uses to recognize germs and help clear them. As a medicine, it is given as immune globulin, purified IgG collected from the donated plasma of many healthy people. Products given into a vein (often called IVIG) include Gamunex-C, Privigen and Gammagard Liquid; Hizentra is given under the skin (subcutaneous immune globulin, or SCIG). Its main use is replacement therapy for primary immunodeficiency, a group of inherited conditions, such as common variable immunodeficiency (CVID) and X-linked agammaglobulinemia, in which the body makes too few working antibodies. Regular infusions supply the missing antibodies to help prevent repeated serious infections. Some products are also approved to prevent bacterial infections in people with chronic lymphocytic leukemia (CLL, a blood cancer) who have low antibody levels or keep getting infections. At higher doses, immune globulin is used to calm certain immune attacks on the body's own tissues. Approved uses include immune thrombocytopenia (ITP), in which the immune system destroys platelets, to raise the platelet count to prevent bleeding or before surgery; chronic inflammatory demyelinating polyneuropathy (CIDP) and multifocal motor neuropathy (MMN), immune-related nerve disorders that cause weakness; and Kawasaki disease in children, to help prevent damage to the heart's arteries. Each brand has its own approved uses and ages, so the right product depends on the condition. A separate product injected into a muscle, GamaSTAN, gives short-term protection after exposure to hepatitis A or measles. Immune globulins made against one specific target, such as Rh immune globulin in pregnancy, are different medicines.
IgG antibodies latch onto specific bacteria, viruses and toxins, neutralizing them or marking them for destruction by immune cells. Because immune globulin is pooled from many donors, it carries antibodies against a very wide range of infections people commonly meet. In someone who cannot make enough of their own, this borrowed protection keeps IgG at a protective level. It does not fix the underlying immune problem, and the body gradually breaks down the infused IgG over several weeks, which is why treatment is repeated on a regular schedule. In autoimmune and inflammatory conditions such as ITP and CIDP, much larger doses are used for a different purpose: to damp down a misdirected immune response. It clearly helps in these conditions, but exactly how it does so is not fully understood.
Doses are based on body weight and the condition being treated. Intravenous infusions are given in a clinic, an infusion center or at home by an infusion nurse, starting slowly and speeding up if they are well tolerated. For primary immunodeficiency, they are usually repeated every 3 to 4 weeks. For ITP, a larger total dose is split over two to five consecutive days. For CIDP, a loading dose over two to four days is usually followed by maintenance infusions, for example every 3 weeks. Subcutaneous immune globulin is infused into the fatty tissue under the skin, often at several sites at once, using a small pump or syringe. After training, many people do it themselves at home, on a schedule anywhere from daily to every 2 weeks for immunodeficiency, or weekly for CIDP with Hizentra. Sticking to the schedule keeps IgG levels steady. For immunodeficiency, the dose is adjusted using how often infections happen and the IgG trough level, a blood test taken just before the next dose, when levels are lowest. Brands differ in strength, approved routes and infusion rates, so one product should not be swapped for another without the prescriber's direction.
With intravenous infusions, the most common reactions are headache, fever, chills, nausea, tiredness, muscle or joint aches and rash, usually during the infusion or within a day or two afterward. Headache is especially common with the high doses used for ITP. Slowing the infusion often helps, and some people are given acetaminophen or an antihistamine beforehand. With subcutaneous infusions, swelling, redness, itching or soreness where the needle went in are expected; a site reaction that gets worse or lasts more than a few days should be reported to the care team. Some less common problems need a call to the care team right away. A severe headache with a stiff neck, fever or sensitivity to light, usually within two days of an infusion, can signal aseptic meningitis, an irritation of the lining around the brain. Dark urine, yellowing of the skin or eyes, or unusual tiredness with a fast heartbeat can mean red blood cells are breaking down. Passing much less urine, sudden weight gain or new swelling can signal kidney strain or fluid overload. Pain, warmth, swelling or discoloration in one arm or leg can be a blood clot. Chest pain, sudden shortness of breath, or numbness or weakness on one side of the body can mean a clot in the lungs or brain or a lung reaction, and need emergency care. Widespread hives, chest tightness, wheezing or lightheadedness can be a severe allergic reaction: during a home infusion, stop the infusion and call 911.
All immune globulin products carry a boxed warning, the most prominent warning the US Food and Drug Administration (FDA) requires, about blood clots in veins or arteries. The risk is higher with older age, long periods of immobility, estrogen-containing medicines, a past clot, a central venous catheter (a long-term IV line), conditions that thicken the blood and heart disease risk factors, though clots can occur without any of these. For people at risk, the care team uses the lowest practical dose and infusion rate and makes sure they are well hydrated beforehand. Intravenous products also carry a boxed warning about kidney damage, including sudden kidney failure. People with existing kidney disease, diabetes, age over 65, dehydration or a severe infection, or who take medicines that can harm the kidneys, are more vulnerable, and products containing sucrose carry more of this risk. Kidney blood tests are checked before the first infusion and periodically afterward. Immune globulin is not given to someone who has had a severe allergic reaction to it. It is also avoided in people with IgA deficiency (lacking a different antibody type, IgA) who have antibodies against IgA and a history of reactions, because even the trace IgA in these products can trigger a severe reaction. The donated antibodies can make some blood tests for infections look positive, and they can weaken the response to live virus vaccines such as measles, mumps and rubella (MMR) and chickenpox, so tell whoever gives a vaccine about recent treatment. Because it is made from human plasma, there is a small risk of passing on an infection, which donor screening, testing and virus-removal steps in manufacturing reduce. There is little data in pregnancy, and it is given then only when clearly needed.
For primary immunodeficiency, immune globulin is usually long-term, because the underlying inability to make antibodies does not go away. The aim is fewer and less severe infections, and the dose is fine-tuned over time using IgG levels and infection history. Some people switch between routes: intravenous treatment means fewer sessions but larger doses and more whole-body reactions, while subcutaneous treatment means more frequent, smaller infusions at home, steadier levels and mostly skin reactions. In ITP, the platelet count is checked soon after treatment, sometimes within a day, to see whether it has risen enough. In CIDP, strength and function are reassessed after the first course; people who respond often continue maintenance infusions, but not everyone needs them beyond about six months, so the ongoing need is reviewed with the care team. First infusions are given slowly with close observation. Over time most people learn which reactions to expect and when. Keeping a log of each infusion, the product lot number and any reactions helps the team spot patterns and adjust the plan.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Immunoglobulin G (IgG), what you've noticed, or ask the community a question.